22 December 2024

Appendix 4G and Corporate Governance Statement (ASX Announcement)

Melbourne, Australia; 22 August 2024: Starpharma (ASX: SPL, OTCQX: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today releases its Appendix 4G, Key Disclosures to Corporate Governance Principles and Recommendations, and Corporate Governance Statement, in accordance with ASX Listing Rules 4.7.3 and 4.10.3.

 

View/download the ASX Announcement: Appendix 4G and Corporate Governance Statement.

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.